Global RNAi for Therapeutic Market Research Report 2023(Status and Outlook)

Global RNAi for Therapeutic Market Research Report 2023(Status and Outlook)



Report Overview

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

The Global RNAi for Therapeutic Market Size was estimated at USD 176.00 million in 2022 and is projected to reach USD 2162.67 million by 2029, exhibiting a CAGR of 43.10% during the forecast period.

Bosson Research’s latest report provides a deep insight into the global RNAi for Therapeutic market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global RNAi for Therapeutic Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the RNAi for Therapeutic market in any manner.

Global RNAi for Therapeutic Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

RXi Pharmaceuticals

Silence Therapeutics

Benitec Biopharma

miRagen Therapeutics

Sylentis

Gradalis

Sirnaomics

Silenseed

Market Segmentation (by Type)

siRNA

miRNA

shRNA

Market Segmentation (by Application)

Wires & Cables

Packaging

Consumer Goods

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the RNAi for Therapeutic Market

Overview of the regional outlook of the RNAi for Therapeutic Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of RNAi for Therapeutic
1.2 Key Market Segments
1.2.1 RNAi for Therapeutic Segment by Type
1.2.2 RNAi for Therapeutic Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 RNAi for Therapeutic Market Overview
2.1 Global Market Overview
2.1.1 Global RNAi for Therapeutic Market Size (M USD) Estimates and Forecasts (2018-2029)
2.1.2 Global RNAi for Therapeutic Sales Estimates and Forecasts (2018-2029)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 RNAi for Therapeutic Market Competitive Landscape
3.1 Global RNAi for Therapeutic Sales by Manufacturers (2018-2023)
3.2 Global RNAi for Therapeutic Revenue Market Share by Manufacturers (2018-2023)
3.3 RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global RNAi for Therapeutic Average Price by Manufacturers (2018-2023)
3.5 Manufacturers RNAi for Therapeutic Sales Sites, Area Served, Product Type
3.6 RNAi for Therapeutic Market Competitive Situation and Trends
3.6.1 RNAi for Therapeutic Market Concentration Rate
3.6.2 Global 5 and 10 Largest RNAi for Therapeutic Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 RNAi for Therapeutic Industry Chain Analysis
4.1 RNAi for Therapeutic Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of RNAi for Therapeutic Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 RNAi for Therapeutic Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global RNAi for Therapeutic Sales Market Share by Type (2018-2023)
6.3 Global RNAi for Therapeutic Market Size Market Share by Type (2018-2023)
6.4 Global RNAi for Therapeutic Price by Type (2018-2023)
7 RNAi for Therapeutic Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global RNAi for Therapeutic Market Sales by Application (2018-2023)
7.3 Global RNAi for Therapeutic Market Size (M USD) by Application (2018-2023)
7.4 Global RNAi for Therapeutic Sales Growth Rate by Application (2018-2023)
8 RNAi for Therapeutic Market Segmentation by Region
8.1 Global RNAi for Therapeutic Sales by Region
8.1.1 Global RNAi for Therapeutic Sales by Region
8.1.2 Global RNAi for Therapeutic Sales Market Share by Region
8.2 North America
8.2.1 North America RNAi for Therapeutic Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe RNAi for Therapeutic Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific RNAi for Therapeutic Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America RNAi for Therapeutic Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa RNAi for Therapeutic Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Alnylam Pharmaceuticals
9.1.1 Alnylam Pharmaceuticals RNAi for Therapeutic Basic Information
9.1.2 Alnylam Pharmaceuticals RNAi for Therapeutic Product Overview
9.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Product Market Performance
9.1.4 Alnylam Pharmaceuticals Business Overview
9.1.5 Alnylam Pharmaceuticals RNAi for Therapeutic SWOT Analysis
9.1.6 Alnylam Pharmaceuticals Recent Developments
9.2 Arbutus Biopharma (Tekmira)
9.2.1 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Basic Information
9.2.2 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product Overview
9.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product Market Performance
9.2.4 Arbutus Biopharma (Tekmira) Business Overview
9.2.5 Arbutus Biopharma (Tekmira) RNAi for Therapeutic SWOT Analysis
9.2.6 Arbutus Biopharma (Tekmira) Recent Developments
9.3 Arrowhead
9.3.1 Arrowhead RNAi for Therapeutic Basic Information
9.3.2 Arrowhead RNAi for Therapeutic Product Overview
9.3.3 Arrowhead RNAi for Therapeutic Product Market Performance
9.3.4 Arrowhead Business Overview
9.3.5 Arrowhead RNAi for Therapeutic SWOT Analysis
9.3.6 Arrowhead Recent Developments
9.4 Dicerna Pharmaceuticals
9.4.1 Dicerna Pharmaceuticals RNAi for Therapeutic Basic Information
9.4.2 Dicerna Pharmaceuticals RNAi for Therapeutic Product Overview
9.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Product Market Performance
9.4.4 Dicerna Pharmaceuticals Business Overview
9.4.5 Dicerna Pharmaceuticals RNAi for Therapeutic SWOT Analysis
9.4.6 Dicerna Pharmaceuticals Recent Developments
9.5 Mirna Therapeutics
9.5.1 Mirna Therapeutics RNAi for Therapeutic Basic Information
9.5.2 Mirna Therapeutics RNAi for Therapeutic Product Overview
9.5.3 Mirna Therapeutics RNAi for Therapeutic Product Market Performance
9.5.4 Mirna Therapeutics Business Overview
9.5.5 Mirna Therapeutics RNAi for Therapeutic SWOT Analysis
9.5.6 Mirna Therapeutics Recent Developments
9.6 Quark Pharmaceuticals
9.6.1 Quark Pharmaceuticals RNAi for Therapeutic Basic Information
9.6.2 Quark Pharmaceuticals RNAi for Therapeutic Product Overview
9.6.3 Quark Pharmaceuticals RNAi for Therapeutic Product Market Performance
9.6.4 Quark Pharmaceuticals Business Overview
9.6.5 Quark Pharmaceuticals Recent Developments
9.7 RXi Pharmaceuticals
9.7.1 RXi Pharmaceuticals RNAi for Therapeutic Basic Information
9.7.2 RXi Pharmaceuticals RNAi for Therapeutic Product Overview
9.7.3 RXi Pharmaceuticals RNAi for Therapeutic Product Market Performance
9.7.4 RXi Pharmaceuticals Business Overview
9.7.5 RXi Pharmaceuticals Recent Developments
9.8 Silence Therapeutics
9.8.1 Silence Therapeutics RNAi for Therapeutic Basic Information
9.8.2 Silence Therapeutics RNAi for Therapeutic Product Overview
9.8.3 Silence Therapeutics RNAi for Therapeutic Product Market Performance
9.8.4 Silence Therapeutics Business Overview
9.8.5 Silence Therapeutics Recent Developments
9.9 Benitec Biopharma
9.9.1 Benitec Biopharma RNAi for Therapeutic Basic Information
9.9.2 Benitec Biopharma RNAi for Therapeutic Product Overview
9.9.3 Benitec Biopharma RNAi for Therapeutic Product Market Performance
9.9.4 Benitec Biopharma Business Overview
9.9.5 Benitec Biopharma Recent Developments
9.10 miRagen Therapeutics
9.10.1 miRagen Therapeutics RNAi for Therapeutic Basic Information
9.10.2 miRagen Therapeutics RNAi for Therapeutic Product Overview
9.10.3 miRagen Therapeutics RNAi for Therapeutic Product Market Performance
9.10.4 miRagen Therapeutics Business Overview
9.10.5 miRagen Therapeutics Recent Developments
9.11 Sylentis
9.11.1 Sylentis RNAi for Therapeutic Basic Information
9.11.2 Sylentis RNAi for Therapeutic Product Overview
9.11.3 Sylentis RNAi for Therapeutic Product Market Performance
9.11.4 Sylentis Business Overview
9.11.5 Sylentis Recent Developments
9.12 Gradalis
9.12.1 Gradalis RNAi for Therapeutic Basic Information
9.12.2 Gradalis RNAi for Therapeutic Product Overview
9.12.3 Gradalis RNAi for Therapeutic Product Market Performance
9.12.4 Gradalis Business Overview
9.12.5 Gradalis Recent Developments
9.13 Sirnaomics
9.13.1 Sirnaomics RNAi for Therapeutic Basic Information
9.13.2 Sirnaomics RNAi for Therapeutic Product Overview
9.13.3 Sirnaomics RNAi for Therapeutic Product Market Performance
9.13.4 Sirnaomics Business Overview
9.13.5 Sirnaomics Recent Developments
9.14 Silenseed
9.14.1 Silenseed RNAi for Therapeutic Basic Information
9.14.2 Silenseed RNAi for Therapeutic Product Overview
9.14.3 Silenseed RNAi for Therapeutic Product Market Performance
9.14.4 Silenseed Business Overview
9.14.5 Silenseed Recent Developments
10 RNAi for Therapeutic Market Forecast by Region
10.1 Global RNAi for Therapeutic Market Size Forecast
10.2 Global RNAi for Therapeutic Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe RNAi for Therapeutic Market Size Forecast by Country
10.2.3 Asia Pacific RNAi for Therapeutic Market Size Forecast by Region
10.2.4 South America RNAi for Therapeutic Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of RNAi for Therapeutic by Country
11 Forecast Market by Type and by Application (2024-2029)
11.1 Global RNAi for Therapeutic Market Forecast by Type (2024-2029)
11.1.1 Global Forecasted Sales of RNAi for Therapeutic by Type (2024-2029)
11.1.2 Global RNAi for Therapeutic Market Size Forecast by Type (2024-2029)
11.1.3 Global Forecasted Price of RNAi for Therapeutic by Type (2024-2029)
11.2 Global RNAi for Therapeutic Market Forecast by Application (2024-2029)
11.2.1 Global RNAi for Therapeutic Sales (K Units) Forecast by Application
11.2.2 Global RNAi for Therapeutic Market Size (M USD) Forecast by Application (2024-2029)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings